Skip to main content

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Recruiting · Phase 2 · NCT07196644

Conditions: Solid Tumors Harboring MET Amplification

At a glance

Research payments reported, 2025
$58,203
U.S. investigators named
2
Sites paid
2
Planned or actual enrollment
100

About the trial

Sponsor
AbbVie
Tested
Telisotuzumab Adizutecan (drug)
Dates
Started 2025-12-01; completion 2030-12
Results posted
Not yet

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of locally advanced or metastatic solid tumors that harbor MET amplification. This study will have 1 arm where participants will receive telisotuzumab adizutecan. Approximately 100 participants 12 years of age or older. with solid tumors harboring MET amplification will be enrolled in the study in up to 50 sites around the world. Participants will receive intravenous (IV) telisotuzumab adizutecan, …

From ClinicalTrials.gov, last updated 2026-08-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $58,203 in research payments for this study in 2025 (2 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Valkyrie Clinical Trials $30,475
  • Duke University $27,728

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.